- UACT statement regarding Chilean Congress resolution calling on the President to advance the compulsory licening request on HCV drugs.
- UACT urges NAFTA delegates to expand access to affordable medicines.
- UACT asked members of US Congress to authorize Medicare price negotiations, backed by compulsory licensing authority.
- UACT and 22 cancer treatment NGOs working in South Africa submitted comments on the Draft South Africa IP Policy.
- UACT delivered a letter to the Chairman and Ranking Member of the US Senate Health, Education, Labor, and Pensions (HELP) Committee regarding the soon-to-be introduced comprehensive health care bill, urging the HELP committee to hold public hearings on how the GOP-led health care reform bill will affect cancer patients.
- UACT and 56 civil society organizations and academic experts call upon the University of California to drop its appeal on the Xtandi patents in India.
- UACT was among 29 civil society organizations and 33 health professionals, activists, and economists — including Nobel Prize laureate Joseph Stiglitz — asking delegates to the World Health Assembly (WHA) to support a feasibility study on the progressive delinkage of the costs of research and development from the price of cancer medicines.
- On April 19, 2017, UACT and KEI sent a letter to Secretary Tom Price of the Department of Health and Human Services, and to Secretary Jim Mattis of the Department of Defense, requesting that the Trump Administration reevaluate the January 2016 Xtandi petition that the government use its rights in patents under the Bayh Dole Act (35 U.S.C. §§ 200 et seq.) for the excessively-priced, blockbuster drug enzalutamide (marketed by Astellas Pharma as Xtandi). Follow our Xtandi page for the latest updates.
- UACT statement on the final report of the UN Secretary-General High-Level Panel on Access to Medicines.
- UACT statement on the GSK announcement regarding licensing cancer drug patents
to the Medicines Patent Pool.
- UACT provided testimony at the hearing for the US Trade Representative’s Special 301 Review process.
- Request for compulsory licences in the UK on the patents for the breast cancer drug Roche’s Kadcyla (T-DM1).